| Literature DB >> 35797463 |
Hartmut Döhner1, Andrew H Wei2, Frederick R Appelbaum3, Charles Craddock4, Courtney D DiNardo5, Hervé Dombret6, Benjamin L Ebert7, Pierre Fenaux8, Lucy A Godley9, Robert P Hasserjian10, Richard A Larson11, Ross L Levine12, Yasushi Miyazaki13, Dietger Niederwieser14, Gert Ossenkoppele15, Christoph Röllig16, Jorge Sierra17, Eytan M Stein18, Martin S Tallman18, Hwei-Fang Tien19, Jianxiang Wang20, Agnieszka Wierzbowska21, Bob Löwenberg22.
Abstract
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35797463 DOI： 10.1182/blood.2022016867
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 25.476